Antithrombin Iii Deficiency

• CLINICAL_TRIALS research · 2024-12-04
  Clinical Trial Update: Belgian Antithrombin Deficiency Registry

  A Belgian registry study to collect data on Antithrombin III deficiency, with recruitment not yet started.

• CLINICAL_TRIALS trial_result · 2023-08-25
  Clinical Trial Update: Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate [Phase 2, Phase 3]

  Phase 2/3 trial updates on safety, pharmacokinetics, and efficacy of an antithrombin III concentrate for antithrombin III deficiency.

• CLINICAL_TRIALS trial_result · 2022-09-07
  Clinical Trial Update: Antithrombin III in Infectious Disease Caused by COVID-19 [Phase 2]

  Phase 2 trial investigating Antithrombin III for infectious disease caused by COVID-19 was terminated; results posted in 2022.

• EMA withdrawal · 2019-07-02
  EMA Withdrawn: ATryn (antithrombin alfa) — Laboratoire Francais du Fractionnement et des Biotechnologies

  The EMA withdrew ATryn (antithrombin alfa) from the market.

• CLINICAL_TRIALS withdrawal · 2017-09-26
  Clinical Trial Update: Atenativ Effect on Uterine Blood Flow and Preeclampsia [Phase 4]

  Phase 4 trial update for Atenativ assessing uterine blood flow and preeclampsia has been withdrawn.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2017-07-26
  Clinical Trial Update: Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery [Phase 2]

  Phase 2 trial evaluating anti-thrombin III versus placebo in young infants undergoing open congenital cardiac surgery has completed with res…

• CLINICAL_TRIALS research · 2017-03-27
  Clinical Trial Update: "Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects"

  A clinical trial update examining the incidence and consequences of disorders of glycosylation in patients with conotruncal and septal heart…